Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03988920 · ClinicalTrials.gov registry record · Phase 4
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
A Phase 4 study of End Stage Renal Disease and Hyperphosphatemia, sponsored by Ardelyx.
- Completed
- Registry status
- Phase 4
- Development phase
- 172
- Enrollment target
- 1
- Study location
NCT03988920 is a Phase 4 study of End Stage Renal Disease and Hyperphosphatemia that has completed, run by Ardelyx. The registered enrollment target is 172 participants, below the 831-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03988920, a Phase 4 study of End Stage Renal Disease and Hyperphosphatemia, has completed, sponsored by Ardelyx.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 172 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is designed to evaluate the ability of tenapanor alone or in combination with sevelamer to achieve serum phosphorus concentration (sP) within the population reference range (sP \>2.5 and ≤4.5 mg/dL) in patients with end-stage renal disease (ESRD) on dialysis with hyperphosphatemia (\>4.5 mg/dL).
Conditions Studied
Interventions
- DRUG Tenapanor
- DRUG Sevelamer Carbonate
Study Locations (1)
California
- Ardelyx Site #509 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2019-06-15 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03988920
The ClinicalTrials.gov registry entry for NCT03988920 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 831-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (79% lower). The listed sponsor is Ardelyx, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 2 interventions - of which Tenapanor is the first listed.
NCT03988920 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03988920 about?
NCT03988920 is a clinical study titled "A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP". The study is designed to evaluate the ability of tenapanor alone or in combination with sevelamer to achieve serum phosphorus concentration (sP) within the population reference range (sP \>2.5 and ≤4.5 mg/dL) in patients with end-stage renal disease (ESRD) on dialysis with hyperphosphatemia (\>4.5 m...
What is the current status of trial NCT03988920?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 172 participants. The study started on 2019-06-15. Estimated completion is 2021-07-31.
What conditions does trial NCT03988920 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Hyperphosphatemia.
What interventions are being tested in trial NCT03988920?
The interventions under investigation include: Tenapanor (DRUG), Sevelamer Carbonate (DRUG).
Who is sponsoring clinical trial NCT03988920?
This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03988920 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ferric Citrate in ESRD Pilot Project
ACTIVE NOT RECRUITING · Phase 4
-
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
ACTIVE NOT RECRUITING · Phase 4
-
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
COMPLETED · Phase 4
-
Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
COMPLETED · Phase 4
-
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
COMPLETED · Phase 4
-
Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.